Dr. Snutch's research is addressing a critical gap in Frontotemporal Dementia (FTD), a fatal brain disease with no available treatments.
In many patients, a genetic mutation disrupts how brain cells communicate early on, likely driving the disease before symptoms fully appear. Right now, we do not fully understand this process or how to stop it.
Given that there are no current treatments for FTD, the hope is to leverage the proof-of-concept studies, together with the late-stage Z944 clinical development, to deliver a promising near-term (2-3 years) therapeutic option for FTD patients.
